Cullman Clinical Trials | Cullman, AL

Research site

Location

501 Clark Street North East, Cullman, Alabama, United States of America

Site insights

Top conditions

Top treatments

S-217622

Cenicriviroc

PF-07817883

Bupropion Hydrochloride

AXA1125

Semaglutide

Naltrexone Hydrochloride

BMS-963272

SAB-185

LY3437943

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

10 of 35 total trials

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symp...

Enrolling

Coronavirus Disease (COVID-19)

Drug: Placebo

Drug: Molnupiravir

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes (ONWARDS 11)

This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investi...

Not yet enrolling

Diabetes Mellitus, Type 1

Drug: Insulin glargine

Drug: Insulin icodec

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Active, not recruiting

Seasonal Influenza

Biological: Fluarix Tetra

Biological: Fluarix®

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2)

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have o...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Retatrutide

A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis (Nova 301)

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Active, not recruiting

Acute Gastroenteritis

Norovirus Acute Gastroenteritis

Biological: mRNA-1403

Biological: Placebo

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation (COURAGE)

This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (...

Active, not recruiting

Obesity

Drug: Matching Placebo-Trevogrumab

Drug: Matching Placebo-Garetosmab

Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt (QUALITY)

The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 recep...

Active, not recruiting

Obesity

Muscle Loss

Drug: Semaglutide

Drug: Enobosarm

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (INFORMUS)

A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).

Enrolling

Obesity

Drug: Placebo

Drug: Naltrexone-Bupropion (NB) Combination

Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VX-993 in participants with pain associated with Diabetic Peripher...

Enrolling

Diabetic Peripheral Neuropathic Pain

Drug: Placebo (matched to pregabalin)

Drug: Placebo (matched to VX-993)

Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications (NAVIGATE)

The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared...

Active, not recruiting

Influenza

Combination Product: CD388 Injection

Combination Product: Placebo